Indian Journal of Private Psychiatry

Register      Login

VOLUME 16 , ISSUE 2 ( July-December, 2022 ) > List of Articles


A Study of Safety and Efficacy of Methylphenidate in Children and Adolescents: An Observational Clinical Study

Akshay Chordia, Sagar Karia, Nilesh Shah, Avinash De Sousa

Keywords : Appetite, Attention deficit hyperactivity disorder, Methylphenidate, Weight

Citation Information : Chordia A, Karia S, Shah N, De Sousa A. A Study of Safety and Efficacy of Methylphenidate in Children and Adolescents: An Observational Clinical Study. Ind J Priv Psychiatry 2022; 16 (2):56-60.

DOI: 10.5005/jp-journals-10067-0115

License: CC BY-NC 4.0

Published Online: 31-08-2022

Copyright Statement:  Copyright © 2022; The Author(s).


Background: Attention deficit and hyperactivity disorder (ADHD) leads to various problems like academic underachievement, interpersonal relationship problems, and low self-esteem. Medications like methylphenidate (MPH) used for its treatment have decreased appetite and weight loss as the main side effects. There is scarce literature that throws light on the prevalence or severity of these particular side effects in patients with ADHD. Aims and objectives: So this study was conducted to assess the safety and efficacy of MPH in children and adolescents diagnosed with ADHD. Materials and methods: Patients of age-group 5–17 years who were diagnosed with ADHD were included in the study after taking informed consent of their parents. Semistructured pro forma was used to collect demographic and phenomenological details. Conners rating scale was used to assess ADHD severity. Methylphenidate was started for treating ADHD and patients were followed up at 1 and 3 months and change in Conners scale and side effects including appetite changes were asked for on follow-ups. Also, height and weight were measured on all visits. Results: One-hundred and seven patients with a mean age of 9.61 years were enrolled; of which, 79% of them were males. Seventy-three percent of them had a combined type of ADHD. The mean dose of MPH increased on subsequent follow-ups. Forty percent of them experience a decrease in their appetite at 1 month but only 18% of them had appetite issues at 3 months. There were no statistically significant changes in the height and weight of the patients on follow-ups. Conclusion: MPH is a very well-tolerated treatment for ADHD and not many side effects are observed in children taking it. Appetite reduction is seen for the initial treatment period which can be managed by giving MPH after heavy breakfast and meals.

PDF Share
  1. Hasson R, Fine JG. Gender differences among children with ADHD on continuous performance tests: a meta-analytic review. Journal of attention disorders 2012;16(3):190–198.
  2. Barkley RA, Cunningham CE. The effects of methylphenidate on the mother-child interactions of hyperactive children. Arch Gen Psychiatry 1979;36(2):201–208. DOI: 10.1001/archpsyc.1979.01780020091010.
  3. Sergeant J. From DSM-III attentional deficit disorder to functional defects. Attention deficit disorder: criteria, cognition, and intervention. New York: Pergamon; 1988. p. 183–198.
  4. Organisation mondiale de la santé, World Health Organization, WHO Staff, WHO. The ICD-10 classification of mental and behavioural disorders: clinical descriptions and diagnostic guidelines. World Health Organization; 1992.
  5. Faraone SV, Sergeant J, Gillberg C, et al. The worldwide prevalence of ADHD: is it an American condition? World Psychiatry 2003;2(2):104. PMID: 16946911.
  6. Zuvekas SH. Prescription drugs and the changing patterns of treatment for mental disorders, 1996–2001. Health Aff 2005;24(1):195–205. DOI: 10.1377/hlthaff.24.1.195.
  7. Guzman F. Methylphenidate for ADHD: mechanism of action and formulations. 2018.
  8. Dam M, Kolmos K, Bilenberg N. Does test dose of central stimulant influence Continuous Performance Test (CPT) and activity in boys with attention deficit hyperactivity disorder. Clin Psychiatry 2016;2(3).
  9. Rubia K, Halari R, Mohammad AM, et al. Methylphenidate normalizes frontocingulate underactivation during error processing in attention-deficit/hyperactivity disorder. Biol Psychiatry 2011;70(3):255–262. DOI: 10.1016/j.biopsych.2011.04.018.
  10. Poulton A. Growth on stimulant medication; clarifying the confusion: a review. Arch Dis Child 2005;90(8):801–806. DOI: 10.1136/adc.2004.056952.
  11. Gianarris WJ, Golden CJ, Greene L. The Conners’ Parent Rating Scales: a critical review of the literature. Clin Psychol Rev 2001;21(7):1061–1093. DOI: 10.1016/s0272-7358(00)00085-4.
  12. Visser SN, Danielson ML, Bitsko RH, et al. Trends in the parent-report of health care provider-diagnosed and medicated attention-deficit/hyperactivity disorder: United States, 2003–2011. J Am Acad Child Adolesc Psychiatry 2014;53(1):34–46. DOI: 10.1016/j.jaac.2013.09.001.
  13. American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-IV-TR. 4th ed. Washington, DC: American Psychiatric Association; 2000.
  14. Barkley RA. Comorbid disorders, social and family adjustment, and subtyping. Attention-deficit hyperactivity disorder: a handbook for diagnosis and treatment. 2006. p. 184–218.
  15. Gaub M, Carlson CL. Gender differences in ADHD: a meta-analysis and critical review. J Am Acad Child Adolesc Psychiatry 1997;36(8):1036–1045. DOI: 10.1097/00004583-199708000-00011.
  16. Sandberg S, editor. Hyperactivity and attention disorders of childhood. Cambridge University Press; 2002.
  17. Quinn PO. Attention-deficit/hyperactivity disorder and its comorbidities in women and girls: an evolving picture. Curr Psychiatry Rep 2008;10(5):419–423. DOI: 10.1007/s11920-008-0067-5.
  18. Biederman J, Mick E, Faraone SV, et al. Influence of gender on attention deficit hyperactivity disorder in children referred to a psychiatric clinic. Am J Psychiatry 2002;159(1):36–42. DOI: 10.1176/appi.ajp.159.1.36.
  19. Sciutto MJ, Eisenberg M. Evaluating the evidence for and against the overdiagnosis of ADHD. J Atten Disord 2007;11(2):106–113. DOI: 10.1177/1087054707300094.
  20. Biederman J, Kwon A, Aleardi M, et al. Absence of gender effects on attention deficit hyperactivity disorder: findings in nonreferred subjects. Am J Psychiatry 2005;162(6):1083–1089. DOI: 10.1176/appi.ajp.162.6.1083.
  21. Gershon J, Gershon J. A meta-analytic review of gender differences in ADHD. J Atten Disord 2002;5(3):143–154. DOI: 10.1177/108705470200500302.
  22. Hinshaw SP, Owens EB, Sami N, et al. Prospective follow-up of girls with attention-deficit/hyperactivity disorder into adolescence: evidence for continuing cross-domain impairment. J Consult Clin Psychol 2006;74(3):489. DOI: 10.1037/0022-006X.74.3.489.
  23. Rucklidge JJ. Gender differences in attention-deficit/hyperactivity disorder. Psychiatr Clin North Am 2010;33(2):357–373. DOI: 10.1016/j.psc.2010.01.006.
  24. Sciutto MJ, Nolfi CJ, Bluhm C. Effects of child gender and symptom type on referrals for ADHD by elementary school teachers. J Emot Behav Disord 2004;12(4):247–253. DOI: 10.1177/10634266040120040501.
  25. Baker K. Conduct disorders in children and adolescents. Paediatr Child Health 2013;23:24–29.
  26. Spencer TJ, Wilens TE, Biederman J, et al. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 2006;28(2):266–279. DOI: 10.1016/j.clinthera.2006.02.011.
  27. Busch B, Biederman J, Cohen LG, et al. Correlates of ADHD among children in pediatric and psychiatric clinics. Psychiatr Serv 2002;53(9):1103–1111. DOI: 10.1176/
  28. Biederman J, Faraone SV, Milberger S, et al. Is childhood oppositional defiant disorder a precursor to adolescent conduct disorder? Findings from a four-year follow-up study of children with ADHD. J Am Acad Child Adolescent Psychiatry 1996;35(9):1193–1204. DOI: 10.1097/00004583-199609000-00017.
  29. Canadian attention deficit hyperactivity disorder resource alliance (CADDRA): Canadian ADHD practice guidelines [Internet]. 3rd ed. Toronto, Canada: CADDRA; 2011.
  30. Stein MA, Sarampote CS, Waldman ID, et al. A dose-response study of OROS methylphenidate in children with attention-deficit/hyperactivity disorder. Pediatrics 2003;112(5):e404. DOI: 10.1542/peds.112.5.e404.
  31. Douglas VI, Barr RG, Amin K, et al. Dosage effects and individual responsivity to methylphenidate in attention deficit disorder. J Child Psychol Psychiatry 1988;29(4):453–475. DOI: 10.1111/j.1469-7610.1988.tb00737.x.
  32. Gurbuz F, Gurbuz BB, Celik GG, et al. Effects of methylphenidate on appetite and growth in children diagnosed with attention deficit and hyperactivity disorder. J Pediatr Endocrinol Metab 2016;29(1):85–92. DOI: 10.1515/jpem-2015-0171.
  33. Sonuga-Barke EJ, Halperin JM. Developmental phenotypes and causal pathways in attention deficit/hyperactivity disorder: potential targets for early intervention? J Child Psychol Psychiatry 2010;51(4):368–389. DOI: 10.1111/j.1469-7610.2009.02195.x.
  34. Leddy JJ, Waxmonsky JG, Salis RJ, et al. Dopamine-related genotypes and the dose–response effect of methylphenidate on eating in attention-deficit/hyperactivity disorder youths. J Child Adolesc Psychopharmacol 2009;19(2):127–136. DOI: 10.1089/cap.2008.046.
  35. Ahmann PA, Waltonen SJ, Theye FW, et al. Placebo-controlled evaluation of Ritalin side effects. Pediatrics 1993;91(6):1101–1106. PMID: 8502509.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.